News

Roquefort Therapeutics PLC was established in 2020 with the principal strategy of developing pre-clinical next generation medicines focused on hard-to-treat cancers. During the period until early 2025, the Company advanced this strategy through acquisitions and the in-house development of several pre-clinical programs.

In early 2025 the Board of the Company unanimously resolved to pivot the strategy of the Company away from pre-clinical programs to clinical stage programs. To initiate the new clinical stage strategy the Company began identifying and assessing suitable clinical stage opportunities. This exercise culminated with the execution of the License Agreement in November 2025, granting the Company the AO-252 Licence.

Acquisition, Change of Name and Admission of the New Ordinary Shares

On 2nd March 2026, the Proposed Acquisition and Conditional Fundraise of £8.5 million was announced and the on 27th March 2026, completion of the Acquisition of Licence from Coiled Therapeutics, Inc., change of name to Coiled Therapeutics PLC, Admission of the New Ordinary Shares and dealings in the Enlarged Share Capital on AIM commenced.

Having helped Roquefort with the production of their prospectus when they floated on the Main Market of the LSE in March 2021, their Acquisition of Oncogeni Limited, Placing and Admission circular in September 2022 and their annual report since December 2021, the Perivan shareholder communications team was delighted to work with SP Angel Corporate Finance who acted as Nominated Adviser and Joint Broker on the 153-page admission document which included the provision of the Engage data room platform which was utilised for the secure proof distribution at this further stage of their corporate journey.

For further information, click here.

Perivan is the market-leading provider of New Issue and IPO admission document production, having maintained its leadership position for six consecutive years.